Arvinas ARVN Bavdegalutamide (ARV-110) — Program-specific external expense

Similar metrics at other companies

IDYADarovasertib — External Clinical Development Expenses

$23.33M+1.4%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

IDYAIDE034 — External Clinical Development Expenses

$6.81M+17,816%

ANROALTO-203 — Direct external program expenses:

$6K-99.2%

CTMXCx904Egfrxcd3 — Total External Costs

$241K-78.3%

ANROALTO-207 — Direct external program expenses:

$4.14M—

Questions, answered.

What is Arvinas's bavdegalutamide (ARV-110) — program-specific external expense?

Arvinas (ARVN) reported bavdegalutamide (ARV-110) — program-specific external expense of $200K in Q1 2026.

How has Arvinas's bavdegalutamide (ARV-110) — program-specific external expense changed year-over-year?

Arvinas's bavdegalutamide (ARV-110) — program-specific external expense decreased by 81.8% year-over-year, from $1.1M to $200K.

What is the long-term trend for Arvinas's bavdegalutamide (ARV-110) — program-specific external expense?

Over 2 years (2023 to 2025), Arvinas's bavdegalutamide (ARV-110) — program-specific external expense has grown at a -68.1% compound annual growth rate (CAGR), from $26.6M to $2.7M.

What does bavdegalutamide (ARV-110) — program-specific external expense mean?

This metric represents the direct external costs, such as clinical trial site fees, contract research organization services, and manufacturing expenses, specifically attributable to the development of a single drug candidate. It serves as a key indicator of the capital intensity and clinical stage progression of a specific therapeutic program within the company's pipeline. Monitoring these costs helps investors assess the resource allocation efficiency and the financial commitment required to advance a specific asset toward regulatory approval.